Signals
5Allergic bronchopulmonary aspergillosis management widens past corticosteroids and itraconazole
Biologic therapy in ABPA, novel azole maturity, and structured diagnostic-and-monitoring pathways are reshaping allergic bronchopulmonary aspergillosis management.
Severe COPD biologic therapy class emerges past the inhaler era
Dupilumab COPD approval in eosinophilic phenotype, mepolizumab and benralizumab COPD pivotal data, and ensifentrine entry are reshaping severe COPD management.
Chronic rhinosinusitis with nasal polyps biologic class matures
Dupilumab maturity, mepolizumab and benralizumab CRSwNP indications, omalizumab CRSwNP approval, and emerging mechanism programs are reshaping CRSwNP management.
Pediatric severe asthma biologic options expand
Dupilumab, mepolizumab, benralizumab, and tezepelumab paediatric label expansions plus emerging biologic programs are restructuring paediatric severe asthma.
Tezepelumab uptake in type-2-low severe asthma is the field's defining commercial test
Tezepelumab's upstream mechanism (anti-TSLP) reaches patients in the type-2-low phenotype that the downstream biologic class cannot effectively serve. Real-world commercial uptake in this previously underserved population is the test of whether the upstream-mechanism advantage translates from clinical evidence to commercial reality.
Snapshots
2Allergic bronchopulmonary aspergillosis therapy reference (2026)
Reference snapshot of ABPA therapy across acute, recurrent, and emerging biologic-integrated tiers.
Severe COPD therapy reference (2026)
Reference snapshot of severe COPD therapy across foundational inhaler, biologic, and emerging mechanism tiers.